Harnessing Gene-Editing Technology for Oncology Trials
The gene-editing technology has captured the attention of the life science and investment communities not only as an elegant tool in the classical science sense — simple and precise — but also as efficient and easy to use, relative to its predecessors. The ethics and policies surrounding the capability of CRISPR-Cas9 to edit the DNA of any cell are also of interest. CRISPR-Cas9 readily promises to enable or improve the ability to decipher the underlying genetic control, diagnosis and interventions of many diseases, including cancers. And, while no clinical trial of a CRISPR-Cas9-enabled cancer therapeutic has begun, discovery and development programs are underway.
This paper explores the possible applications of CRISPR-Cas9 technology within the oncology clinical trial arena.
Submit this form for download.